NYSE:PRX Pharmaceutical Resources (PRX) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free PRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume277,372 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pharmaceutical Resources alerts: Email Address Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Pharmaceutical Resources Stock (NYSE:PRX)Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.Read More Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. PRX Stock News HeadlinesMay 13 at 5:36 PM | msn.com‘Life after cancer’: Nigerian survivors challenge taboos, push for better health careMay 9, 2024 | msn.comNvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To KnowMay 7, 2024 | msn.comClosing Bell: ASX rallies hard as RBA holds rates; Bonza drama continues with court rulingMay 6, 2024 | msn.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call TranscriptMarch 12, 2024 | msn.comPharmacies getting back on track after Change Healthcare hackFebruary 25, 2024 | msn.comARS Pharmaceuticals (SPRY) Price Target Increased by 56.25% to 12.75January 29, 2024 | tmcnet.comPharmaScroll Unveils Groundbreaking Expansion of Key Opinion Leader Database: Empowering Pharmaceutical Industry with Cutting-Edge Market InsightsJanuary 4, 2024 | msn.comIberdrola terminates $8.3bn PNM Resources mergerJanuary 2, 2024 | businesswire.comRocket Pharmaceuticals to Present at 42 nd Annual J.P. Morgan Healthcare ConferenceDecember 21, 2023 | msn.comCAN, CALT and PRZO are among pre market gainersNovember 26, 2023 | msn.comRecursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.October 24, 2023 | businesswire.comPre-Sterilized/Ready to Use Pharmaceutical Packaging Market, 2035 - ResearchAndMarkets.comOctober 24, 2023 | msn.com2 pharmaceutical companies to pay $120M in 3rd Kentucky settlementSeptember 26, 2023 | benzinga.comSpherix Introduces Patient Chart Dynamix™, an Enhanced Independent Pharmaceutical Market Research Chart AuditSeptember 15, 2023 | msn.comWhy Crinetics Pharmaceuticals Stock Soared This WeekSeptember 4, 2023 | businesswire.comPharmaceutical Temperature-Controlled Packaging Market, 2028 - Pharma TCP Market Digitization to Cut Costs and Streamline Processes - ResearchAndMarkets.comMay 17, 2023 | marketwatch.comGlobal Drug and Pharmaceutical Machinery Market 2023-2030 by Size|Precisionreports.coMay 14, 2023 | marketwatch.comPharmaceutical Cartridges Market by 2030May 11, 2023 | marketwatch.comPharmaceutical Labeling Market Research | 2023-2030May 11, 2023 | marketwatch.comPharmaceutical Inks Market Research | 2023-2030May 11, 2023 | marketwatch.comLatest Updates on Pharmaceutical outsourcing Market from Industry Experts | 2023 to 2030May 11, 2023 | marketwatch.comPharmaceutical Grade Dextran Market Future Scope and Growth Status 2031May 11, 2023 | msn.comChina Resources Pharmaceutical Group (3320) Price Target Increased by 10.39% to 8.07May 8, 2023 | marketwatch.comDrug and Pharmaceutical Machinery Market Size, 2030May 5, 2023 | marketwatch.comPharmaceutical Contract Packaging Market Research Findings to 2030See More Headlines Receive PRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaceutical Resources and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:PRX CUSIPN/A CIK878088 Webwww.parpharm.com Phone+1-845-5735500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesPaul V. Campanelli (Age 54)Chief Executive Officer Michael A. Tropiano (Age 57)Chief Financial Officer, Executive Vice President Terrance John Coughlin (Age 52)Chief Operating Officer Thomas J. Haughey (Age 51)Chief Administrative Officer, General Counsel PRX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pharmaceutical Resources own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmaceutical Resources investors own include Gol Linhas Aéreas Inteligentes (GOL), WildHorse Resource Development (WRD), Baidu (BIDU), Amicus Therapeutics (FOLD), U.S. Global Investors (GROW), Inovio Pharmaceuticals (INO), Monster Beverage (MNST), Rite Aid (RAD), Rocket Companies (RKT) and (APKT) (APKT). This page (NYSE:PRX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaceutical Resources Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.